

SpeakOut

The newsletter of Oracle Cancer Trust



LEADING RESEARCH INTO HEAD AND NECK CANCER

AUTUMN 2016

“Until I was diagnosed with mouth cancer, I’d never heard of it”

Jack Wild 1952-2006

Widow of late actor Jack Wild pledges to continue her support raising awareness of mouth cancer following her husband’s death.

Spotted by a theatrical agent playing football in the 1960s, Jack Wild went on to become one of the most famous child actors of his generation, best known for his role in the 1968 movie production as the Artful Dodger in the hit movie Oliver!

His autobiography, which is being published this November, is the product of 21 years work and has been completed by his widow, Claire. Jack had what he called his “lost decade” in the 1980s fighting alcoholism and, following a period in rehabilitation, started work on his book. He was sober for the last 17 years of his life.

In 2001, Jack confronted the biggest battle of his life when he was struck down by oral cancer, which he blamed on his years of drinking and smoking. Following radiotherapy which significantly affected his speech and swallowing, the cancer returned and Jack was faced with surgery of the tongue which was followed by a total laryngectomy leaving him unable to speak, or eat and drink without a feeding tube.

Following his diagnosis in 2001, Jack was passionate about raising awareness of oral cancer, which his wife is now dedicating to supporting in his memory.

Claire explains “When Jack was diagnosed with cancer of the tongue he blamed only himself after the years of struggling with alcoholism and smoking, but he’d never heard of it. What he realised quite quickly was that his lifestyle had made him a walking time bomb.”



“The combination of drinking and smoking made a lethal combination. The only symptom Jack had was persistent earache.”

“I am delighted to be supporting Oracle Cancer Trust in their vital role in raising awareness for head and neck cancer and their vital research to improve treatments.”


Jack’s autobiography “*It’s a Dodger’s Life*” is available now.

Facts about Oral Cancer

- There were 7,500 cases of oral cancer in 2013
- 21 cases of oral cancer are diagnosed daily in Great Britain
- Since the late 1970’s cases have increased by 92% in Great Britain with most cases being linked to lifestyle factors such as drinking and smoking

Warning Signs

- An ulcer or sore in your mouth, or red or white patch that doesn’t heal
- An unexplained pain in your mouth or ear, or lump in your neck
- Sore or painful throat
- Croaky voice or difficulty swallowing



Research Projects Update



Oracle Patron HRH Princess Alexandra to attend our 11th Glory of Christmas Concert



Walkers enjoy summer temperatures and raise over £5k for Oracle



Ride for Oracle at the 2017 Prudential RideLondon-Surrey 100 Classic



Farewell to outgoing Voluntary CEO Anthony Sykes

Dear Oracle Supporters,

I joined Oracle Cancer Trust in June 2012, initially to chair the Fundraising Committee and subsequently to become its voluntary CEO. I am now handing over to my successor, Jamie Newall, to grow the charity and enable it to accomplish its mission to become recognised as a Centre of Excellence for early-stage funding of head and neck cancer research projects, without which the development of better ways to save the lives and preserve the quality of life of head and neck cancer patients would not be possible.



During my term of office my priorities have been:

1. To strengthen the internal management and operation of the Charity to ensure that our financial management and internal governance processes are well established
2. To establish a three year business plan to provide clarity on our structure and short term objectives
3. To implement a more sustainable funding basis for the Charity
4. To develop an overall strategic plan for the Charity

The Charity has invested heavily over the past two years in strengthening its financial management and reporting function. The independent examination of the Charity's annual accounts is now carried out by the well-known firm of Kingston Smith who have a leading position in the charity sector.

Our governance processes have been carefully put in place to ensure that management decisions are taken by internal committees which are independently chaired and appropriately resourced to avoid any conflicts of interest.

Our three year Business Plan was approved by the Board at the start of 2016 and this gives the Board, the Management Team and the various committees of the Charity a working document to chart where we are heading and how we propose to get there. The business plan has now been supplemented by the Strategic Review which was prepared for Oracle on a pro bono basis by professional management consultants. The Strategic Review provides management with market information about the overall head and neck cancer sector, the activities of charities working within the sector and the position of Oracle within the sector so that decisions can be taken on an informed basis about how to develop Oracle in the future.

Finally, I am pleased that during my tenure as Chief Executive of the Charity we were able to launch the first loans-based endowment scheme for a charity in the UK, through which Oracle supporters are able to make five year, interest free loans to Oracle, which are invested with a professional fund manager, and provide Oracle with an annual return of about four percent. This initiative offers a further option to supporters who want to support the activities of the Charity without having to gift away, or lose control of their capital. We believe that this is an innovative way towards sustainable funding for charities and we are proud that Oracle has been a pathfinder in the sector.

I am, therefore, delighted to be able to hand over the reins of the Charity to Jamie Newall who has a Cambridge law degree and a history of senior appointments including Founding Director of an offshore fund, Chief Operating Officer of a listed gold exploration company and Investments Director for a major private equity firm. Jamie has outstanding financial credentials and the experience necessary to provide Oracle with the management it needs to go forward.

I believe that, through these initiatives and through your support, Oracle is now in very good shape and is in an excellent position to achieve its goal of helping head and neck cancer sufferers. I would like to take this opportunity to thank all of you for your help in the past and ask for your continuing support for Jamie and the Oracle team in the future.

With best wishes,

Anthony Sykes

Welcome to our new Voluntary CEO, Jamie Newall



Oracle's new Voluntary CEO
Jamie Newall

Welcome to our Autumn newsletter and my first as CEO of Oracle Cancer Trust. I would like to start by paying tribute to Anthony Sykes on his retirement as CEO. Over the past four years Anthony has worked tirelessly for Oracle, supported at all times by his wife Nancy.

The CEO role at Oracle is a pro-bono role and therefore Anthony's achievements during his tenure are all the more impressive. His development of the loans based Endowment Fund was ground-breaking and was the first for a UK charity. The financial and research governance procedures he has put in place mean that Oracle can boast of internal governance that would be the envy of most corporations. However, to me his greatest achievement is the incredible team he has built around him, both in the office, on our various committees and on the Board. We all wish Anthony and Nancy a relaxing and enjoyable retirement and look forward to seeing them both at Oracle events in the future.

I look forward to meeting you at Glory and sharing our exciting plans for the next few years with you in the Spring newsletter.

Professor Harrington's study results in major breakthrough for head and neck cancer treatment

A new drug treatment for head and neck cancer, which has been shown to extend the lives of advanced head and neck cancer patients by up to a year, hit the headlines recently. The drug, Nivolumab, has been described as a potential "game-changer" with promising results presented at the European Cancer Congress in early October. Patients taking Nivolumab survived longer compared to those treated with chemotherapy.

The benefits were more pronounced in patients whose tumours had tested positive for the HPV virus (human papillomavirus). These patients survived an average of 9.1 months with nivolumab and 4.4 months with chemotherapy. In the UK, Nivolumab has only been licenced to treat skin cancer.

Professor Kevin Harrington of the Institute of Cancer Research and consultant at The Royal Marsden Hospital in London, who led the head and neck cancer trial, said Nivolumab could be a real "game-changer" for patients with advanced head and neck cancer.

"This trial found that it can greatly extend life among a group of patients who have no existing treatment options, without worsening quality of life. Once it has relapsed or spread, head and neck cancer is extremely difficult to treat. So it's great news that these results indicate we now have a new treatment that can significantly extend life, and I'm keen to see it enter the clinic as soon as possible."



Dr Kate Newbold joins Oracle as Honorary Trustee



Head and neck Consultant
Clinical Oncologist Dr Kate Newbold

We are delighted to welcome Dr Kate Newbold as an Honorary Trustee, joining Professor Kevin Harrington and Professor Chris Nutting. Dr Newbold is a Consultant Clinical Oncologist specialising in the treatment of patients with cancer of the head and neck and thyroid. Based in London, Dr Newbold operates primarily from The Royal Marsden Hospital. Her research interests include functional imaging applied to the oncological management of head and neck cancer, dosimetric delivery of radioiodine and novel systemic therapies for advanced thyroid cancer.

Says Dr Newbold "I am delighted and honoured to be joining Oracle Cancer Trust as an Honorary Trustee. Oracle funds important research in both head and neck and thyroid cancers and I am excited to be involved in the growth of the charity and its pioneering research programmes."

Welcome to our new PhD funded student




New PhD student Alexandra Rose

PhD student Alexandra Rose has recently started her three-year project under the supervision of Dr Amanda Swain and Professor Kevin Harrington. The aim of Alexandra's project will be to understand the progression of Adenoid Cystic Carcinoma (ACC) of the salivary gland and to discover new treatments. Alex was particularly drawn to this project as improved therapies are urgently needed for ACC, with the 15 year survival rate being just 40%. One reason for this low rate is that ACC recurrence is common and often spreads to the lungs and perineural space, where the tumour develops chemotherapy resistance, which significantly reduces treatment options.

By carrying out this PhD project, Alex aims to investigate the mechanism of drug activity of ACC growth and identify new therapies targeted to specific tumour mutations.

Says Alex "I am extremely excited to be undertaking a PhD at the ICR, the number one academic research centre in the UK and am finding it exciting jumping straight into lab work."

Oracle funds tongue cancer study



Deciding on the course of treatment for patients with tongue cancer has historically presented clinicians with some difficult questions - do you pre-empt the spread of the cancer to the neck and perform preventive surgery? Or wait for the disease to spread before performing surgery and avoid unnecessary treatment but reducing the likelihood of survival?

Addressing this problem, Oracle has agreed to fund the next stage of a study into tongue cancer metastases at Addenbrooke's Hospital in Cambridge. In patients with tongue cancer, the cancers can spread to the neck region. This spread is often indicated by the presence of neck lymph nodes which can be detected clinically or radiologically. However, some patients with these tongue cancers - known as squamous cell carcinomas - present at the clinic with no neck lymph nodes detectable.

This presents a surgeon or oncologist with a dilemma. Do they observe those patients without treating the neck and wait for any spread of the disease to become apparent or do they pre-empt the spread of the disease and treat the patient with a neck dissection or irradiation, a course of action known as prophylactic treatment? Both these approaches risk either under- or over-treating these patients. Prophylactic treatment can be a risk. However, a spread to the neck of the cancers can decrease survival by 50%.

Up to now there has been little evidence to help the physician decide which would be the best approach to use in individual cases. As part of an approach to address this issue, Oracle has been funding a pioneering study by surgeon, Furrat Amen.

Furrat is a consultant ENT, head and neck and thyroid surgeon at Peterborough City Hospital and Addenbrooke's Hospital in Cambridge. Over the last four years, Furrat has collected and analysed the case notes and tumour samples from 200 patients with squamous cell carcinoma of the tongue. Some of these patients had developed metastases to the neck; others didn't.



Dr Furrat Amen

The next stage of Furrat's work, for which Oracle has agreed funding, will involve chemically staining these tumour samples and applying antibodies to determine whether differences exist in the genes expressed by the tumours from which metastases did and didn't develop. By determining whether different genes are found for patients who did and didn't develop metastases or whether there is any link between the genes expressed and patient survival, it is hoped that a method can be developed to guide treatment of the neck for patients, based upon analysis of their initial cancer biopsy specimen.

Oracle to fund exciting “Biomarker” imaging project



Non-invasive imaging techniques can capture information about the tumour to help clinicians plan treatment plans for patients

Dr Gabriela Kramer-Marek leads new Oracle funded trial where cancer cells “light up” using sophisticated imaging techniques

This new study will look at how imaging can be used to identify which head and neck cancer patients may be more likely to respond to treatments.

The treatment of head and neck squamous cell carcinomas (HNSCC) is mainly based on surgery and/or radiotherapy. In many cases, chemotherapy or targeted therapy drugs such as cetuximab are added to radiotherapy to make it work more effectively.

However, despite the fact that standard treatments are generally used, the responses of tumours are highly variable. Clinical results show that only a small fraction of patients benefit from these targeted therapies due to the tumours evolving to acquire resistance during treatment.

If there was a way of predicting who would respond to which treatment, treatments could be tailored to the individual patient. In this way, there could be a reduction of exposure of unresponsive patients to the unnecessary side effects of ineffective, expensive treatments.

Choosing treatments for patients

Although treatment decisions are often based on biopsy specimens taken from tumours, this may not be an accurate reflection of the way that a patient’s disease will respond to treatment.

This is because different parts of the tumour may have a slightly different genetic make-up based on the different mutations that can occur as the tumour grows. This phenomenon is called “intratumoural heterogeneity” and is a major reason that anti-cancer treatments fail.

Introducing Imaging

Professor Harrington and Professor Kramer-Marek of the ICR believe that a biomarker based on non-invasive imaging tests is far more likely to capture information on the heterogeneity of the disease and be useful in the clinic.

In recent years, molecular imaging technologies have emerged with the ability to assess heterogeneity of tumours. The best example is positron emission tomography (PET) that allows non-invasive evaluation of a range of tumour characteristics, also known as ‘biomarkers’, such as metabolism, hypoxia, receptor status and proliferation.

These biomarkers can help clinicians to select the most appropriate initial treatment and provide information on how well that treatment is working. Dr Gabriela’s team believes that the predictive and/or prognostic value of these biomarkers will inform and guide treatment decisions in patients with HNSCC, ensuring that treatments are personalised.



PET scanners are used to provide detailed 3-D images

Under the supervision of Dr Kramer-Marek and Professor Harrington, Oracle will be funding the post-doctoral student Dr Carlos Daniel Martins to compare multiple imaging biomarkers and assess their predictive value as surrogate markers of tumour resistance/sensitivity in guiding the treatment of head and neck cancer.

Musical Evening Fundraiser

Over 65 guests joined us for a beautiful late summer's evening at 22 Mansfield Street, set in the heart of London's Marylebone at the private home of Mr and Mrs Bob Boas, to enjoy a range of musical classics courtesy of leading soprano Helena Dix accompanied by pianist and conductor Anthony Negus. Native Australian Helena entertained the audience with her witty insights into the history of the music which included classical opera from Verdi and Puccini through to modern show tunes.

Following the performance, guests enjoyed a reception where there was a prize draw which included a stunning Italian handbag kindly donated by designer Vassi8, an iPad donated by IT company WeSeeNow and a whole host of other prizes, including signed Nigella cookery books.

The evening raised over £2,700 and thanks go to Mr and Mrs Bob Boas who generously hosting the event and to Patrick Allen of Connaught Artists for providing artists Helena Dix and Anthony Negus.

To see the gallery from the evening please visit www.oraclecancertrust.org/opera2016



Helena Dix with accompanist Anthony Negus



Soprano Helena Dix entertains



Ian and Carole Kent-Robinson with Mrs Deirdre Donegan



The upstairs drawing room at 22 Mansfield Street



Professor Chris Nutting with Oracle's new CEO Jamie Newall



(L to R) Michael de Nabarro, Dina Longden and Patrick Allen

Oracle Cancer Trust Golf Day

Our eighteen teams couldn't have asked for better conditions at the annual Golf Day in late September at the stunning Burhill Golf Club in Surrey. The sun shone throughout and the course was in superb condition giving our golfers a testing round of golf on the scenic and undulating Old Course. The on course challenge "Beat the Pro" raised £590 and thanks go to IT company WeSeeNow for sponsoring the welcome bags for the golfers.

The day was held in memory of golf day founder Derek Lucie-Smith who sadly lost his brave and long battle with cancer earlier this year. In memory of Derek, Oracle founded the "Derek Lucie-Smith Memorial Trophy", a replica of the famous Open Claret Jug which this year was won by Julian Buck. The day raised over £7,000 and we look forward to welcoming golfers of all standards to our day in 2017.

To see pictures from the day visit www.oraclecancertrust.org/2016golfday

Save the date!

**Thursday 28th
September 2017
The Old Course,
Burhill Golf Club**

**10am shotgun start
Golf, entertainment and
three course meal
£550 fourball team
£140 individual player**



Conditions were perfect on the day



(L) Damon Jarrett with his team



Sarah White with Claire Vincent of "Team Tradition"



Bob Howes and his team "Fulham 1879"

Annual Supporters Research Event

Over 60 supporters joined the Oracle team recently at our second annual research event where project leaders and researchers presented their Oracle funded head and neck projects. Professor Uwe Oelfke, Professor Caroline Springer, Dr Imran Petkar and Professor Kevin Harrington delivered inspirational and thought-provoking talks on changes in cancer treatment and how we are now closer than ever to finding effective treatments. Following the presentations guests had the opportunity to meet the researchers and hear about their projects in more detail.

To see the gallery from the evening visit www.oraclecancertrust.org/researchevent2016



Emma Colliver welcomes the audience to our second research event



(L) Robin Gooch with Jill Loveday and Mary Gooch



(L) Dr Imran Petkar, Dr Ketan Shah with Dr Simon Robinson



(L) Caroline Bogh-Henrikssen with Peter Rhys Evans and Sarah Goldschmied



(L) Mrs Julia Travers-Wakeford with researcher Joan Kyula

11th Glory of Christmas Concert Monday 5th December



We are delighted to announce that our Patron, HRH Princess Alexandra will be attending our 11th Glory of Christmas Concert at the beautiful concert venue of St John's Smith Square in London SW1.

Our annual Christmas event is an opportunity for supporters and patients to join the Oracle team as well as funded researchers and staff.

Come and enjoy music from the Thames Chamber Orchestra and the acclaimed Choir of Christ's College, Cambridge with harpist Deian Rowlands and violinist David Juritz.

Ticket prices range from £45, £30, £15 and £10 with a special offer of four £30 tickets for £100.



Tickets can be booked as follows:
www.oraclecancertrust.org/boxoffice
events@oraclecancertrust.org
Call us on 020 7922 7924



Supporter Fundraising

Carswell Gould's Massif Challenge raises over £1,200



The four riders cycled up to 230 miles a day over three days

Four members of Southampton-based marketing agency Carswell Gould took on "The Massif Challenge", a three day, 500 mile ride that starts at the Channel port of St. Malo in France and finishes at Clermont-Ferrand, taking in the sights of Normandy, the Loire Valley and the Massif Central, following several of the stages of the 2016 Tour de France.

Oracle Cancer Trust was chosen by the team as particularly close to their hearts after the managing director of one of Carswell Gould's clients passed away from throat cancer.

Dan, who led the team said "The challenge was one of the toughest cycling routes I've ever done, but it's for a great cause and the sheer amount of support we've had from friends, family and clients has been amazing. Seeing all the support and donations that have been coming in has made it even more worthwhile."



Carswell Gould present Emma Colliver with the cheque

Following the ride, donations continued to roll in and the Carswell Gould team was proud to hand over a cheque for £1,200 to Emma Colliver, Head of Fundraising at Oracle Cancer Trust.

Following their Massif Challenge experience, Carswell Gould have announced that they intend to form an ongoing partnership with Oracle to continue raising vital funds for the charity's work.

Friends and family enjoy an afternoon tea party and raise over £4,000

In early September, Mohan and Shirlu Mahtani invited family and friends for a tea party



Mrs Mahtani's artwork, inspired by her life in Nigeria

After he was treated for laryngeal cancer by Peter Rhys Evans in 2014, Mohan Mahtani and his wife Shirlu pledged their support to Oracle, passionate about raising funds and awareness for the charity's work.

Says Mrs Mathani "The team treating my husband Mohan had done so much for us and

we wanted to give something back as we felt we had benefited so much from the research and new treatments. We were overwhelmed by the support from friends and family who joined us, and those who donated but were unable to attend."

Homemade tea and snacks were served to over 30 guests who came to support Mr and Mrs Mahtani on a very wet Saturday afternoon. As well as asking guests to donate to attend, Shirlu organised a lucky dip and also sold a selection of her own paintings to guests, inspired by the passion for painting which she had fostered whilst the family lived in Nigeria.

In addition, Shirlu's grandchildren sold their own hand-painted pashminas and designs to guests.

Donations from those unable to make the event helped to boost the fundraising total further still, helping Mohan and Shirlu to achieve a grand total of over £4,000.



Mohan and Shirlu Mahtani's grandchildren Sujai and Alisha sell their handmade pashminas

Head of Fundraising, Emma, said 'It was a pleasure to meet Mohan and Shirlu, along with so many of their family and friends. Oracle is very grateful for the couple's efforts in spreading the word and raising funds to support our valuable work and I couldn't resist buying one of the beautiful painted pashminas myself!'



Mohan Mahtani

Supporter Fundraising

Supporters raise over £5,000 walking The Test Way



Young walker Seb, completing his second Test Way walk is interviewed by local radio

On Sunday 9th October, a team of 33 supporters stepped into their walking boots to walk Romsey's scenic Test Way route, raising over £5,000 for Oracle. The Walk the Test Way event, hosted annually by the Rotary Club of Romsey Test, saw over 700 walkers take on routes ranging in length from five miles to 16 miles on a sunny day worthy of the height of summer.

One of Oracle's walkers, taking part for the second year running was three year old Seb who walked five miles in memory of his two great-grandfathers, both of whom passed away from cancer. After completing the five mile walk, Seb told the local radio station that "Oracle helps people with poorly heads and necks feel better". His parents, Jamie and Gemma, also walking said "The more we can do to help support research into this horrible disease, the better."



Anne O'Reardon and friends walked in memory of Anne's late husband Steve

Oracle's Linda Wimble and Emma Colliver greeted the finishers with well-earned afternoon buffet kindly donated by an Oracle supporter.

Medals were presented to all of the walkers on completion of their chosen distance by Lady Penelope Brabourne of Brooklands. Jamie Newall, joining the Oracle Team on the walk three days before he became CEO, said "We felt proud and privileged to be part of a great day enjoying the beautiful surroundings. To have raised £5,000 was a magnificent effort and we are immensely grateful to all those who took part for making it possible."

If you would like to show your support of the Oracle team's efforts, you can make a donation at www.justgiving.com/fundraising/OracleWalksTheTestWay.

We look forward to walking with supporters in 2017.

Join us in 2017 on
Sunday October 8th



(L) Damon Jarrett with his daughter Immy being presented with a finisher's medal



Nicola Ridges-Jones (centre) leads the march to the finish after completing 16 miles



A walker awarded a finishing medal by Lady Brabourne of Hampshire's Broadlands Estate



(L) Oracle team members Emma Colliver with Linda Wimble at the finish line for the hungry walkers

Hamish Greenwood's fundraising total exceeds £13,000

Taking part in a Triathlon is not a decision to be taken lightly but when Hamish Greenwood's father was diagnosed with cancer of the tongue, Hamish reasoned that raising funds for Oracle Cancer Trust was the best way to say thank you for the care he had been given throughout his treatment. Not content with taking part in any old triathlon, Hamish entered the Austrian Ironman Triathlon which took place in June this year and comprised a 3.9km swim followed by a 180km bike ride and a full marathon to finish.

To his enduring credit, Hamish completed the triathlon in record time, raising over £13,000 for Oracle Cancer Trust. Chairman, Peter Rhys Evans said, "Hamish raised an incredible amount of money for us and we are incredibly proud to have been chosen as the beneficiary charity. Fundraising on this sort of scale is amazing and we are extremely grateful to Hamish as well as all his family and friends who sponsored him so generously."



Hamish Greenwood training in Bahrain for the Austrian Ironman Triathlon

“Up, down and all around” walk in memory of Nigel Sampson

On Sunday 23rd October 2016, friends and family gathered to take part in a six mile walk in memory of Nigel Sampson who lost his battle with head and neck cancer on 14th July 2016, aged 56.



113 people and beloved hounds joined together for the walk titled ‘Up Down & All Around with Nigel’, which was part of the Isle of Wight Walking Festival.

Nigel discovered a lump on the left side of his neck in 2011, which was diagnosed as a secondary cancer site, the primary site being unknown. He was given two months to two years to live. The news was devastating and really knocked us for six, suddenly our world was turned upside down and the future was unknown. Nigel had a neck dissection in October 2011, followed by chemotherapy and radiotherapy. A PET scan later identified the primary site on the back of the tongue.

Nigel suffered a further set back when it was discovered the cancer had spread to his lungs and bones. Having completed a further programme of treatments he was referred to The Royal Marsden London to consider the possibilities of taking part in clinical trials. It was during this visit that it was discovered that a weakness in Nigels legs was due to a tumour pressing on the spine. Nigel was transferred to The Queen Alexander Hospital London for emergency spinal surgery.

The surgeon explained the only option was to operate and remove the tumour to relieve the pressure on the spine and explained there was a risk of nerve damage. Radiotherapy would initially cause swelling and due to the proximity of the tumour with the spinal nerve this was not an option. It felt like we were on a rollercoaster that we couldn’t get off of, it was just one challenge after another.

Following spinal surgery, Nigel was accepted onto a clinical trial at The Royal Marsden under the care of Professor Harrington. It was during his attendance for his second course of treatment that investigation established the tumour on his spine had returned. He was referred for radiotherapy treatment which meant his part in the trial was suspended.

Nigel endured many challenges over his five year illness, from dealing with the effects of chemotherapy and radiotherapy including a lack of appetite, loss of taste, difficulty with eating resulting in feeding through a food tube, hair loss and immense fatigue. The treatment was brutal and the feelings of despair seeing a loved one

struggling to eat and cope with everyday activities through immense fatigue is just heartbreaking. In addition watching someones life being turned on its head, one minute enjoying life, being active and socialising with family and friends and the next having to consider everything you do and whether you have the energy to do it.



Nigel really fought his disease and wanted to keep life as normal as possible. He continued to work as an Industrial Radiographer throughout his illness until 2016.



Nigel was so dignified and courageous in how he dealt with his battle, he never lost his sense of humour and continued to put everyone before himself right to the end. He was a true inspiration to everyone that knew him.

Head and neck cancer is such a horrible, devastating disease that affects so many people. More needs to be done to help the development of early stage treatment.



I am delighted to support Oracle Cancer Trust and its vital work funding research to develop newer and kinder treatments.

Fundraise for Oracle

Prudential RideLondon-Surrey 100 - Ride for Oracle in 2017



Oncologist Dr Shree Bhide and Professor Kevin Harrington are keen cyclists and are taking up the challenge for Oracle

Oracle has secured several charity ballot places for the 5th annual Prudential RideLondon-Surrey 100 bike race which takes place on Sunday 30th July 2017. Celebrating the legacy for cycling created by the London 2012, the Prudential RideLondon-Surrey 100 takes place on closed roads in the capital and Surrey's stunning countryside. With leg-testing climbs and a route made famous by the world's best cyclists at the London2012 Olympic Games, it is a truly spectacular event for all involved.

Professor Kevin Harrington and Oncologist Dr Shree Bhide cycle regularly together and are taking up the challenge to raise funds for Oracle for the 2017 ride. Would you like to join them? There is no registration fee to ride for Oracle but we are seeking a minimum sponsorship commitment of £1,500 per rider.

More than 26,000 cyclists are expected to be on the start line for the 2017 Prudential RideLondon-Surrey 100. Riders will start in Queen Elizabeth Olympic Park and finish on The Mall in St James's Park, central London, shortly before 150 professional cyclists race in the Prudential RideLondon-Surrey Classic on an extended version of the route.

Don't miss this unique opportunity to get involved in one of biggest cycling events in the UK that last year raised over £12m for good causes in 2015.

Would you like to join us?

If you'd like to know more or sign up, then please contact Emma Colliver emma@oraclecancertrust.org or call us on 020 7922 7924.

Join us in 2017
for the Prudential
RideLondon



Celebrate and donate in aid of Oracle this season

With the Christmas season nearly upon us, why not hold a festive fundraiser in aid of Oracle this year? We've got plenty of ideas for simple fundraisers to help you raise vital funds for head and neck cancer research while having festive fun besides!

Festive Feast

Why not be inspired by the Mahtani's charity tea party and hold a festive buffet for family and friends? Ask everyone to bring a Christmas bake or festive food or to brew a glass of mulled wine. Collect donations on the door or in return for food. Ask local stores or companies for raffle prizes or challenge the kids to do some festive artwork which you auction off at the event.

Christmas Quiz

Looking for a festive fundraiser for your company? Why not hire out a local venue and host your own Christmas Quiz? You could have a 'Name that Christmas #1' music round and a Christmas taste test round to add a twist to your event before crowning the Christmas Quiz Champions.

Santa Dash

Or, if you're pre-empting the festive feasting, why not kick-start December with a 5k fun run in aid of Oracle? Signing up to the Santa Dash, you'll be provided with your own Santa suit to run in, with a variety of race locations and dates to choose from. Get sponsored to enjoy this festive fun run and raise funds for research.

Dates and details can be found at: <http://www.santadash.co.uk>

If you'd like to discuss these or any of your own festive fundraising ideas, get in touch with Head of Fundraising, Emma, at emma@oraclecancertrust.org or call us on 020 7922 7924.



Pledge

PLEDGE

Legacy Giving

Oracle Cancer Trust is truly grateful for the compassion of anyone who leaves a gift in their will, whatever its value. Today's legacy gifts will help us to find better treatments and new cures for future generations of patients suffering from head and neck cancer.

Donate

DONATE

Online

You can now make a one-off donation or set up a regular donation directly via our website at www.oraclecancertrust.org/donate

Payroll Giving

Payroll Giving is easy to set up. There's no direct debit, no gift aid, and just one form to complete. Payroll giving will let your payroll department, and us, know that you want to start donating. Donations can be active within around 4-6 weeks of your instruction.

Shop and Donate for free with easyfundraising

Did you know that you can shop and raise funds for Oracle at the same time? Easyfundraising has joined forces with thousands of well-known retailers who have in turn agreed to pay a small commission towards the charity of your choice at no extra cost to you.

See www.easyfundraising.org for more information.

Eat out and Donate - book using www.charitablebookings.org

Whether for business or pleasure, enjoy making restaurant reservations via the Charitable bookings app where an incredible **£1 for EVERY diner** will be donated by the restaurant to a charity of your choice at absolutely no cost to you. Visit www.charitablebookings.org for more information or visit the App or Android store to download the app.

Lend

LEND

The Oracle Endowment Fund

Please consider supporting the creation of an endowment fund for Oracle Cancer Trust by joining existing lenders with a five year interest-free loan to the charity. Contact Jamie Newall at jamie@oraclecancertrust.org to find out more.

Nominate

NOMINATE

Nominate Oracle as your Company's Charity of the Year

Many companies now pledge to support one or more chosen charity partners over the course of a year. Oracle is looking to establish its first Corporate Charity Partnerships and we need your help in securing our place on the nomination list.

Let us know which company you work for and anything you know about your company's charitable activity and we can provide the information you need to support a nomination for Oracle Cancer Trust. What's more, **we look to offer bespoke business benefits to our corporate partners** including event invitations, lab tours, tailored fundraising ideas and PR support, helping to recognise your business's CSR achievements and support a successful and memorable year of fundraising.

Get in touch with emma@oraclecancertrust.org to discuss how Oracle could work with your company and visit www.oraclecancertrust.org/fundraise/corporate-partnerships

FIND US ONLINE: oraclecancertrust.org

Oracle Cancer Trust, 32-36 Loman Street, London SE1 0EH

Telephone: 020 7922 7924

Email: info@oraclecancertrust.org

Registered charity 1142037

Leading Research into Head and Neck Cancer

